India Approves First Dengue Vaccine QDENGA for People Aged 4 to 60 Years

A Major Public Health Milestone

India has taken a giant leap forward in its continuous war against mosquito-borne diseases with the official market authorisation of its first-ever dengue vaccine. The Drug Controller General of India (DCGI) approved Takeda Biopharmaceuticals’ QDENGA (TAK-003) for use in a wide population. QDENGA is a live-attenuated tetravalent vaccine intended to provide protection against all four distinct dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) in persons 4-60 years of age.

Administration without Pre-screening Streamlined

One of the most important clinical benefits of QDENGA is its easy deployment in high-burden countries. Unlike older generations of dengue vaccines that needed complex blood tests to confirm prior infection before they were administered, QDENGA can be given to people regardless of whether they have had dengue before. This removes the need for any pre-vaccination screening, making it much more practical for both large-scale public immunisation campaigns and private clinical settings.

Dosage, Effectiveness, and What To Do Next

It's given as two injections under the skin. The second injection is given 3 months after the first injection. Clinical trials and long-term follow-up data spanning several years have shown strong efficacy against symptomatic infection and serious complications that require hospitalisation.

With India accounting for a large share of the global dengue burden and sharp seasonal spikes every year, QDENGA’s arrival adds an important new line of defence. Public health experts stress that while vector control, community awareness and surveillance are still critical,